Date of report 09 Oct 2019

Reported case interaction between
Raltegravir and Eslicabazepine

52 year-old HIV-infected patient on treatment with raltegravir (1200 mg QD) plus FTC/TAF since July 2018. HCV co-infection, no liver function impairment. Paranoid schizophrenia and depressive syndrome on treatment with paliperidone, mirtazapine and lorazepam. Epilepsy with recurrent seizures despite treatment with different anticonvulsants (phenytoin, phenobarbital). On treatment with eslicarbazepine (1200 mg QD) since October 2014, with no subsequent seizures. Despite potential decrease in raltegravir exposure due to mild UGT induction by eslicarbazepine, the patient maintains complete viral suppression (plasma viral load <40 copies/mL, October 2019). Although it has not been studied, co-administration of eslicarbazepine with raltegravir might result in potential decrease in raltegravir concentrations and eventual failure of antiretroviral treatment. In cases without alternative options of effective antiretroviral and anticonvulsant therapy, there is a need for close monitoring of viral load.